CDXC Nov 2024 7.500 call
- Business Wire
ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
LOS ANGELES, May 23, 2024--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy-aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.
- Business Wire
ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award
LOS ANGELES, May 22, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, is proud to announce that its flagship ingredient, Niagen® (patented nicotinamide riboside, NR), the most efficient and high-quality NAD+ booster and the active ingredient in the company’s consumer supplement, Tru Niagen®, has been awarded the NutraIngredients EU Healthy Ageing Ingredient of the Year Award. This recognition underscores the signifi
- GuruFocus.com
ChromaDex Corp (CDXC) Q1 2024 Earnings: Aligns with EPS Projections, Misses Revenue Estimates
Insights into ChromaDex's First Quarter Financial Performance and Strategic Initiatives
